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Dear Editor,
A 64-year-old woman presented with isolated thrombocy-
topenia and was diagnosed to have immune thrombocyto-
penic purpura (ITP). There was a slow but relentless
deterioration of her platelet count. Two years later, she
was found to have splenomegaly and a platelet count of
23×109/L. Positron emission tomography/computed to-
mography showed multiple mildly hypermetabolic masses
in the spleen and liver. Splenectomy and liver biopsy
were performed. The spleen showed sinusoidal infiltra-
tion by large tumour cells with abundant foamy cyto-
plasm and active erythrophagocytosis. Tumour cells
were positive for the histiocytic markers lysozyme,
CD68 and CD163. Liver was also involved. Features
were consistent with histiocytic sarcoma. Marrow exam-
ination showed the presence of large histiocytic cells
with haemophagocytosis (Fig. 1a), which were CD68
positive (Fig. 1b). Haematopoiesis appeared otherwise
normal. Her platelet count recovered briefly after sple-
nectomy, but soon deteriorated to <10×109/L, which
was associated with frequent and distressing bleeding.
Several chemotherapeutic regimens comprising cyclo-
phosphamide, doxorubicin, vincristine, etoposide, cytar-
abine, bleomycin, methrotrexate, gemcitabine, cisplatin
and prednisolone failed to alleviate the severe throm-
bocytopenia. Reassessment marrow examination showed
the persistence of abnormal histiocytic cells, some
reaching enormous sizes (Fig. 1c). She was finally
started on the thrombopoietin mimetic eltrombopag
(50 mg/day). The platelet count responded within a
fortnight, rising to about 40×109/L. Since then, she had
remained asymptomatic with stable platelet counts while on
eltrombopag.
This patient initially presented with what appeared to
be ITP. However, the gradual deterioration and the
finding of a splenomegaly prompted further investiga-
tions [1], which showed an infiltrative lesion in the
spleen and liver. With the diagnosis of histiocytic sar-
coma, marrow examination was performed, showing
histiocytic infiltration. Therefore, the thrombocytopenia
was attributed to marrow infiltration, although the ex-
tremely low platelet counts were incongruent with the
preserved haematopoiesis. Intensive chemotherapy did
not improve the platelet count or decrease the histio-
cytes. We surmised that the thrombocytopenia might
instead be due to haemophagocytosis, and therefore
after all was similar to ITP in that excessive destruction
of platelets was the pathogenetic mechanism. She was
treated with eltrombopag as for ITP refractory to sple-
nectomy [2], and achieved a satisfactory response. Al-
though eltrombopag cannot be expected to impact on
the histiocytic sarcoma, it has significantly improved the
quality of life of the patient and relieved her of severe
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thrombocytopenia and bleeding. Finally, although bone
marrow examination may not be recommended for the
majority of patients presenting with features characteris-
tic of ITP [1], the judicious performance of this proce-
dure may be necessary in patients with atypical features,
particularly in the elderly.
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Fig. 1 Histiocytic sarcoma
infiltrating the bone marrow.
a Histiocytic cell showing
haemophagocytosis. b
Immunohistochemical staining
showing infiltration of the
marrow by CD68-positive cells
(immunoperoxidase). c Enor-
mous histiocyte showing active
haemophagocytosis
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